On Day 3 after injection of TTI-621, the patient noted a 20% reduction in the size of the injected tumor. There was a decrease in the percentage of Sézary cells (CD4+CD26-) in the peripheral blood from 56.2% before injection of TTI-621 to 26.9% on Day 3 and 5.8% on Day 5. These changes were accompanied by a transient increase in CD11b+CD14+ macrophages in the peripheral blood from 3.9% before injection to 6.1% on Day 3, which returned to baseline by Day 7. The administration of PEGylated Interferon-a2a on day 7 after TTI-621 decreased the Sézary cell count from 52.5% to 0.62% on day 14, which was accompanied by an improvement in erythroderma as well as the resolution of dysesthesia of the skin that patient experienced at baseline. A significant increase in the percentage of NK cells (CD56+CD3-) and naïve CD8+ cells (CCR7+CD45RO-) was observed following injection of TTI-621 by day 7, and also observed 7 days after PEGylated Interferon-a2a. One week following the injection of PEGylated Interferon-a2a, all tumors had regressed completely.
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM